☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
everest medicines
Everest Medicines Report the NDA Acceptance of Nefecon by the Taiwan FDA for the Treatment of Primary IgA Nephropathy
December 27, 2023
Pfizer’s Etrasimod Receives the US FDA’s Approval for Adults with Moderately to Severely Active Ulcerative Colitis
October 17, 2023
Everest Medicines Receives the NMPA Recommendation of Priority Review for Cefepime-Taniborbactam to Treat Complicated Urinary Trac...
September 20, 2023
Everest Medicines Partner Calliditas Publish P-III (NeflgArd) Trial Results of Nefecon for Primary IgA Nephropathy in The Lancet
August 18, 2023
PharmaShots Weekly Snapshots (July 24 – 28, 2023)
July 29, 2023
Everest Medicines Reports the Commercial Availability of Xerava (eravacycline) in China
July 27, 2023
Load more...
Back to Home
Modal title
×
Modal body text goes here.